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Introducción: la nutrición enteral es una intervención efectiva para pacientes desnutridos o en riesgo de sufrir desnutrición. Sin embargo, puede 
desencadenar complicaciones como intolerancia gastrointestinal, hiperglicemia o síndrome de realimentación. 
Objetivo: investigar los efectos de una fórmula de nutrición enteral por sonda en el estado nutricional y bioquímico, hábitos gastrointestinales 
y seguridad de los pacientes.
Metodología: estudio observacional, prospectivo y multicéntrico. Se incluyeron pacientes ≥ 18 años, desnutridos o en riesgo de desnutrición, 
tributarios de recibir una fórmula de nutrición enteral hipercalórica, hiperproteica, y rica en fibra y fructooligosacáridos. Los pacientes fueron 
evaluados durante 8 semanas en 3 visitas (V1, inicial; V2, 4 semanas; V3, 8 semanas).
Resultados: entre V1 y V2 se observó un incremento estadísticamente significativo en peso (1,5 kg), índice de masa corporal (0,6 kg/m2) e 
ingesta calórica (59,7 kcal/día). Entre V1 y V3, existió un descenso en el porcentaje de pacientes con valores anormales de glucosa, potasio, 
proteína total y albúmina. Los hábitos intestinales se mantuvieron estables durante el estudio (1,1 deposiciones diarias de media).
Conclusión: la fórmula fue segura, tolerada, y mejoró el estado nutricional del paciente sin alterar los hábitos intestinales.
Abstract 
Background: Enteral nutrition (EN) is an effective nutritional intervention for patients at risk of malnutrition or malnourished. However, compli-
cations such as gastrointestinal intolerance, hyperglycemia or refeeding syndrome can be triggered by EN. 
Aim: To investigate the effects of a tube feeding formula (TFF) on patients’ nutritional status, biochemical status, bowel habits and safety. 
Methodology: Observational, prospective and multicenter study. Patients ≥ 18 years, undernourished or at nutritional risk, who were prescribed 
a high-calorie, high-protein, fiber-fortified TFF were included. Patients were evaluated over a period of eight weeks (baseline [V1], four weeks 
[V2] and eight weeks [V3]). 
Results: A statistically significant increase in weight (1.5 kg), body mass index (0.6 kg/m2) and nutritional intake (59.7 kcal/day) was observed 
between V1 and V2. Between V1 and V3, there was a statistically significant decrease in the percentage of individuals with abnormal biochemical 
markers for glucose, potassium, total protein and albumin. The number of patients’ bowel movements remained stable throughout the study with 
a mean of 1.1 daily bowel movements.
Conclusion: The TFF was safe and well tolerated, improving patients’ nutritional status without altering patients’ bowel habits.
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INTRODUCTION
Most medical complications tend to involve a decline in nutri-
tional status. Up to 40% of recently hospitalized patients, in par-
ticular those with chronic diseases, are at risk of malnutrition (1). 
Regarding institutionalized patients, 30% are malnourished and 
49% are at risk of malnutrition (2). Malnutrition can lead to severe 
physical and psychological consequences, and delays recovery 
after surgery and illness; patients’ tolerance of treatment and 
quality of life are reduced, the risk of complications and death 
rises, length of hospital stay increases, and healthcare costs rise 
accordingly (3-5). Malnutrition, among other factors, can be the 
cause and consequence of altered bowel habits, such as diarrhea.
Enteral feeding, alone, or as a supplement to oral feeding, is an 
effective method for providing nutritional support to individuals who 
are undernourished or who are at risk of developing malnutrition. 
Patients who receive enteral nutrition show less weight loss and 
a lower risk of mortality and complications than patients at risk 
of malnutrition who receive normal feeding (3), and this type of 
nutritional intervention is particularly effective if started early (6). 
Enteral nutrition (EN) has been found to be beneficial in patients 
with a wide range of conditions, including burns, chronic obstructive 
pulmonary disease, gastrointestinal surgery or liver diseases (7,8). 
In addition, it has been shown to be safe and cost-effective and, 
since its introduction, it has become an established procedure (9). 
Side effects of EN may include mechanical complications (e.g., 
tube obstruction and perforation of the intestinal tract), infectious 
complications (e.g., aspiration pneumonia and infection at the tube 
insertion site), gastrointestinal disorders (e.g., diarrhea and constipa-
tion) and metabolic complications (e.g., hyperglycemia and refeeding 
syndrome) (10). Intestinal disorders are one of the most common 
complications of EN (11), and are reported to affect 30-60% of 
patients (1,11). Constipation, meanwhile, is very common in patients 
with reduced mobility (12), and is sometimes even more prevalent 
than diarrhea in patients receiving enteral feeding alone (13). These 
complications, aside from the immediate discomfort they cause for 
patients, can trigger additional problems: adequate nutrition may be 
limited and electrolyte imbalances may occur, generating additional 
costs associated with patient care. Fiber-enriched enteral formulas 
can help improve bowel habits, resolve constipation and reduce the 
incidence of diarrhea. However, the effects of fiber in nutritional sup-
plements vary according to the different types of fiber and volumes 
tested (14). Moreover, fiber and fructo-oligosaccharide (FOS)-enriched 
enteral formulas have been shown to increase patient appetite (15), 
and they also have a beneficial effect on the gut microbiota (16).
The aim of this study was to evaluate patient nutritional status, 
effect on bowel habits and the overall safety of a high-calorie, fiber 
and FOS-enriched enteral formula with a high monounsaturated fatty 
acid content (Jevity® Plus HP) in clinical practice in Spanish patients. 
METHODOLOGY
This was an observational, prospective, multicenter study con-
ducted in the Spanish healthcare setting. 
STUDY POPULATION
A total of 102 patients, undernourished or at nutritional risk 
(Nutritional Risk Scale [NRS] ≥ 3) who were prescribed enteral 
nutrition in the form of Jevity® Plus HP (Abbott Laboratories S.A.) in 
routine clinical practice, participated in this study. The duration of 
daily administration of enteral nutrition was 18-20 hours, gradually 
increasing between day 1 and day 3 according to patient tolerability.
Patients were ≥ 18 years old, admitted in the study sites, who 
required EN administered via a nasogastric tube. Study exclusion 
criteria were: patients already receiving EN, and patients with a 
history of gastrointestinal bleeding, bowel obstruction, or changes 
in kidney or liver function (defined as serum creatinine > 2.5 
mg/dl or serum AST at least three times above the upper limit of 
normal). Subjects with unstable vital signs for 48 hours or more 
or with known allergy to any component of Jevity® Plus HP (see 
composition in table I) were also excluded.
The caloric requirements were calculated per each patient with 
the Harris-Benedict equation adjusted for stress factor (from 1.1 
to 1.3) according to medical judgment. EN was continuously sup-
plied. The rate of infusion was progressively increased to reach 
the nutritional goal.
DATA COLLECTION
Patients were evaluated over a period of eight weeks, during 
which three different visits were performed: baseline (V1), at four 
weeks (V2) and at eight weeks (V3). 
In V1, patient demographic characteristics, informed consent 
forms, and clinical history were recorded, and the case report forms 
were provided to the nursing department, to be returned consecu-
tively in V2 and V3. Bowel habits (number of daily bowel movements 
and stool type) were recorded in these case report forms. Diarrhea 
was defined as > 3 liquid bowel movements per day and consti-
pation as < 3 weekly bowel movements. Vital signs, hematological 
parameters and use of laxatives were recorded at the three visits. A 
physical examination was also performed in V1 and V3.
If the investigator decided to withdraw the patient from the 
study before completion (eight weeks), the reasons detected dur-
ing the patient’s final evaluation were fully recorded.
An adverse event (AE) was defined as any worsening of a pre-ex-
isting disease or condition, whether related or not related with the 
treatment administered. All AEs were recorded by the physician 
and classified as mild (transient and easily tolerated by the patient), 
moderate (defined as significant discomfort affecting the patient’s 
usual activities) or serious (incapacitating or life-threatening). Sim-
ilarly, the relationship of the AE with study nutrition was classified 
as probable, possible, unlikely, or unrelated.
ETHICAL CONSIDERATIONS
All patients or legal representatives of patients signed the 
informed consent form prior to beginning the study. Data of all 
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patients were recorded without including their personal details 
in order to maintain patient confidentiality. This post-marketing 
observational study was approved by the Clinical Research Ethics 
Committee of the Hospital Clínico San Carlos, Madrid.
STATISTICAL ANALYSIS
The statistical analysis was performed using the SAS® v9.3 
software package. For continuous variables, mean, standard 
deviation (SD), median, interquartile range (IQR), minimum and 
maximum values were calculated. The Shapiro-Wilk test was used 
to determine the normal distribution of the sample. For qualitative 
variables, absolute or relative frequencies and 95% confidence 
intervals (CI) were calculated. Missing values were excluded.
Differences in quantitative variables between visits were test-
ed by paired t-test or Wilcoxon matched pairs signed rank test. 
Comparisons of quantitative variables between groups were per-
formed by t-test (or the non-parametric Wilcoxon rank sum test). 
In the case of qualitative variables, differences between visits were 
tested by the McNemar’s test and differences between groups, 
by the Chi-squared test. In all cases, the statistical significance 
level was 5%.
Patient percentage with biochemical parameters between the 
standards was based on: glucose, 70-110 mg/dl; sodium, 135-
145 mEQ/l; potassium, 3.5-5.3 mEq/l; chlorine, 96-106 mEq/l; 
gamma-glutamyl transferase (GGT), 6-50 U/l; total protein, 6-8.3 
g/dl; albumin, 34-54 g/l and pre-albumin, 10-40 mg/dl.
RESULTS
PATIENT CHARACTERISTICS 
From the total (n = 102), the more common indication for EN 
were cancer (29.4%), neurodegenerative diseases (22.5%) and 
cardiovascular events (10.8%). Among them, 43.1% were hospi-
talized and 56.9% were outpatients.
In total, 81.4% (n = 83) of the patients included in the study 
completed the eight-week follow-up. The most common causes 
of early withdrawal from the study (excluding missing data from 
the calculations) were adverse events (7.8%; n = 8), of which only 
one was probably due to EN, and death (4.9%; n = 5), unrelated 
to the intervention. At baseline, no significant differences were 
found in age, weight and biochemical markers levels between 
patients who completed the eight-week follow-up and those who 
were prematurely withdrawn.
Of all the participants, 56.9% were women, and median age 
was 78.2 years (IQR 70.4 - 84.7). Anthropometric measurements 
showed the mean weight of patients at the beginning of the study 
was 55.2 (SD: 10.3) kg. Mean body mass index (BMI) was 21.7 
(4.05) kg/m2 (Table II). At the beginning of the study, 30.4% of 
patients needed laxatives throughout the study. Regarding their 
medical history, 10.8% of patients had medication allergies, 
29.4% had cancer, and up to 43.1% had arterial hypertension.
Table I. Formula composition 
 Per 100 mL Per 500 mL 
Energy 131 kcal/551 kJ 655 kcal/2,755 kJ 
Proteins 8.13 g 40.65 g 
Carbohydrates 14.15 g 70.75 g 
Maltodextrin (100%) 
Fats 4.33 g 21.65 g 
MCTs 0.84 g 4.2 g 
Total dietary fiber 0.50 g 2.50 g 
FOS 1 g 5 g 
Water 79.5 g 397 g 
Taurine 15 mg 75 mg 
Carnitine 12 mg 60 mg 
Choline 60 mg 300 mg 
Minerals 
Sodium 100 mg 500 mg 
Potassium 130 mg 650 mg 
Chlorine 130 mg 650 mg 
Calcium 115 mg 575 mg 
Phosphorus 85 mg 425 mg 
Magnesium 25 mg 125 mg 
Iron 1.6 mg 8 mg 
Zinc 1.7 mg 8.5 mg 
Manganese 0.4 mg 2 mg 
Cooper 200 µg 1,000 µg 
Iodine 16 µg 80 µg 
Selenium 8.5 µg 43 µg 
Chromium 7.0 µg 35 µg 
Molybdenum 12 µg 60 µg 
Vitamins 
Vitamin A (Palmitate) 120 µg RE 600 µg RE 
Vitamin A (β-carotene) 30 µg RE 150 µg RE 
Vitamin D3 0.90 µg 4.5 µg 
Vitamin E 2.3 mg α-TE 11 mg α-TE 
Vitamin K1 7 µg 35 µg 
Vitamin C 20 mg 100 mg 
Folic acid 30 µg 150 µg 
Vitamin B1 0.20 mg 1 mg 
Vitamin B2 0.28 mg 1.4 mg 
Vitamin B6 0.29 mg 1.5 mg 
Vitamin B12 0.60 µg 3 µg 
Niacin 2.8 mg NE 14 mg NE 
Pantothenic acid 1 mg 5 mg 
Biotin 6 µg 30 µg 
Osmolarity 305 mOsm/l
MCT: Medium chain triglyceride; FOS: Fructo-oligosaccharides; RE: Retinol 
equivalents; α-TE: α-tocopherol equivalents; NE: Niacin equivalents.
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EFFECT OF NUTRITIONAL FORMULA ON THE 
PATIENT’S NUTRITIONAL STATUS
At the start of the study, 63.7% (n = 65) of patients had expe-
rienced unintentional weight loss. The proportion of patients who 
showed an increase in weight from baseline was 72.3% in V2, 
and 75.3% in V3. Median weight increased significantly by 1 kg 
(IQR 0-2; p < 0.001) between V1 and V2, while between V1 and V3, 
weight increased by 1.5 kg (IQR 0.2-4.0; p < 0.001). Differences 
in weight between V2 and V3 were also statistically significant 
(p < 0.001). Similarly, an increase in BMI values was recorded in 
65.9% of patients in V2 and in 71.6% of patients in V3. Median 
increase was 0.4 kg/m2 (IQR 0.0-0.7; p < 0.001) in V2, and 
0.6 kg/m2 (IQR 0.0-1.5; p < 0.001) in V3 (Table III). The dif-
ferences between V2 and V3 were also statistically significant 
(p = 0.019). Mean caloric requirements increased significantly 
throughout the study, from 1,568 (SD, 298) kcal/day (n = 102) 
at the beginning of the study, 1,610 (SD, 321) kcal/day (n = 90) 
in V2 (p = 0.011) and 1,628 (SD, 328) kcal/day (n = 84) in V3 
(p = 0.034). On average, mean caloric intake exceeded the caloric 
requirements in 99 kcal/day during the first four weeks (1,709 
[SD, 331] kcal/day [n = 102]) and in 151 kcal/day during the last 
four weeks (1,779 [SD, 335] kcal/day [n = 89]). 
In general, no significant changes were found in biochemical 
variables between the three study visits, with the exception of two 
parameters: albumin and pre-albumin. Albumin rose by 1.9 g/l 
(SD, 4.1; p < 0.001) between V1 and V2 and by 3.8 g/l (SD, 5.4; 
p < 0.001) between V1 and V3. Changes were also observed in 
pre-albumin: compared to values recorded in V1, levels rose in 
V2 and V3 by 1.9 mg/dl (SD 6.0; p < 0.001) and by 2.5 mg/dl 
(SD 6.1; p = 0.002), respectively (Table III). Mean albumin values 
were below normal limits at baseline and recovered in V2, while 
the other biochemical parameters analyzed, including glucose, 
remained within normal limits throughout the study.
In general terms, the percentage of individuals with abnormal 
biochemical markers fell throughout the study (Fig. 1). These dif-
ferences were significant between V1 and V3 in patients with 
altered glucose (V1: 29.1% - V3: 11.4% [n = 79]; p = 0.003), 
potassium (V1: 12.8% - V3: 2.6% [n = 78]; p = 0.020), total 
protein (V1: 46.3% - V3 22.2% [n = 54]; p = 0.009) and albumin 
(V1: 54.6% - V3: 31.2% [n = 77]; p < 0.001). Moreover, a fall in 
numbers of patients with abnormal sodium levels was observed, 
but this difference was not significant (V1: 17.9% - V2: 8.9% 
[n = 78]; p = 0.126).
EFFECT OF NUTRITIONAL FORMULA ON 
PATIENTS’ BOWEL HABITS
The percentage of patients with diarrhea, according to clin-
ical criteria, was 4.3% (n = 4, three of them receiving several 
drugs that may cause diarrhea) during the first four weeks 
(weeks 1-4) and 1.1% (n = 1, who received medications that 
may cause diarrhea) during the last four weeks (weeks 5-8) 
(torasemide, clorazepam, amoxicillin, tobramicina, bicaluta-
mide, dexamethasone, granisetron, levodopa and carbidopa). 
This difference was not statistically significant. According to 
data recorded in the patient diary, during the first four weeks 
13.1% (n = 13) of patients had diarrhea during a median of 
two days (IQR 1-2), whereas during the last four weeks, 11.6% 
(n = 10) of patients had diarrhea, with a median duration of 
one day (IQR, 0-2). In both cases, nine of those patients were 
receiving concomitant treatments that may cause diarrhea. 
None of these differences were statistically significant. Mean 
daily number of bowel movements was 1.1 (SD, 0.2) (n = 101) 
during the first four weeks and 1.1 (SD, 0.4) (n = 89) during 
the following four weeks. This difference was not significant 
(p = 0.548).
Table II. Baseline demographic characteristics
Characteristics Percentage Median (IQR) Mean (SD) MD
Sex (women) 56.9% 1
Age (years) 78.2 (70.4-84.7) 0
Weight loss 63.7% 0
Weight (kg) 55.2 (10.3) 0
BMI (kg/m2) 21.7 (4.1) 4
Laxative use 30.4% 0




Alcohol use 4.9% 0
Smoking 5.9% 1
IQR: Interquartile range; SD: Standard deviation; MD: Missing data.
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Table III. Variables at the three visits and changes from visit 1





V1 55.9 (47.2-61.9) 55.2 (10.3) NA NA -
V2 57.1 (49.3-63.5) 56.6 (10.1) 1.2 (3.2) < 0.001* 14
V3 58.6 (50.0-64.4) 57.9 (10.4) 2.3 (3.7) < 0.001* 17
BMI (kg/m2)
V1 21.7 (19.0-23.8) 21.7 (4.1) NA NA -
V2 22.3 (19.5-24.3) 22.2 (4.1) 0.4 (0.9) < 0.001* 17
V3 22.7 (20.0-25.2) 22.7 (4.1) 0.77 (1.2) < 0.001* 21
Sodium (mmol/l)
V1 140 (137-142) 140.3 (4,3) NA NA -
V2 141 (138-142) 140.2 (3.8) 0.0 (0.5) 0.995 19
V3 140 (138-143) 140.3 (3.6) -1.0 (0.5) 0.510 21
Potassium (mmol/l)
V1 4.2 (3.9-4.7) 4.3 (0.6) NA NA -
V2 4.3 (3.9-4.6) 4.3 (0.5) 0.0 (0.0) 0.904 19
V3 4.3 (4.0-4.7) 4.4 (0.5) -0.1 (0.1) 0.196 21
Chlorine (mmol/l)
V1 104 (101-105) 103.5 (4.8) NA NA -
V2 104 (102-106) 103.9 (3.6) -0.6 (0.6) 0.286 60
V3 104 (101-106) 103.4 (4.3) -0.2 (0.7) 0.712 58
Glucose (mg/dl)
V1 91.0 (79.0-109.0) 99.8 (37.0) NA NA -
V2 92.0 (83.0-105.0) 95.5 (16.8) -3.8 (35.6)  0.674 19
V3 92.0 (83.0-102.0) 94.9 (18.1) -3.99 (41.0)  0.954 20
GGT (IU/l)
V1 26.0 (17.0-45.0) 39.7 (36.6) NA NA
V2 29.0 (17.0-49.0) 40.8 (34.7) -2.4 (3.7) 0.509 42
V3 26.0 (16.0-42.0) 44.1 (53.1) -3.3 (4.7) 0.486 41
Total protein (g/l)
V1 6.2 (5.7-6.9) 15.0 (20.0) NA NA -
V2 6.3 (6.0-6.8) 11.0 (16.0) 1.5 (2.0) 0.459 42
V3 6.6 (6.1-6.9) 11.9 (16.6) -0.1 (2.1) 0.956 41
Albumin (g/l)
V1 32.0 (28.0-36.2) 32.2 (5.9) NA NA -
V2 33.1 (31.0-38.3) 34.3 (5.7) 1.9 (4.1) < 0.001* 23
V3 36.0 (32.9-39.0) 36.2 (4.7) 3.8 (5.4) < 0.001* 22
Pre-albumin (mg/dl)
V1 20.9 (14.7-26.3) 20.9 (8.0) NA NA -
V2 21.0 (15.1-28.5) 22.2 (8.5) 1.9 (6.0) < 0.005* 62
V3 22.3 (17.5-26.0) 23.1 (7.4) 2.5 (6.1)  0.002* 62
IQR: Interquartile range; SD: Standard deviation; MD: Missing data; GGT: Gamma-glutamyl transferase; V1: Visit 1; V2: Visit 2; V3: Visit 3. *Statistically significant 
difference.
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PRODUCT SAFETY
In total, 11.8% (n = 12) of patients reported AEs (a total of 
20 AEs were reported including fever [n = 3], infections [n = 6], 
respiratory failure [n = 3], emergency tracheotomy [n = 1], drug 
interaction [n = 1], acute diarrhea [n = 1], death [n = 1] and 
others [n = 4]). Only one (0.9%) of the cases was probably relat-
ed to the EN (drug interaction in a patient with diabetes mellitus 
and chronic anemia). Another patient (0.9%) had acute diarrhea, 
possibly, but not probably, related to EN. One AE reported was 
a case of hyperglycemia, with no proven relationship with the 
enteral formula. 
DISCUSSION
Malnutrition is associated with chronic diseases and other 
complications, including comorbidities and death (17-19). Enteral 
nutrition is a safe and cost-effective intervention to feed patients 
who cannot cover all requirements from food or oral nutritional 
supplements, or who cannot swallow safely (9).
The main aim of using high-calorie and high-protein enteral 
tube feeds containing fiber is to provide appropriate nutritional 
support, and to prevent weight loss, or even achieve weight gain. 
Jevity® Plus HP has been shown to be effective in this setting, 
as most of patients (75.3%) gained weight both in the first four 
weeks after starting the study, and at the end of the study. 
Despite the benefits of enteral feeding, one of the reported 
problems is an increase in episodes of diarrhea and constipation 
(10). However, the diarrhea suffered by patients on EN is often due 
to medication use, infections, problems caused by their under-
lying disease, or the feeding method, rather than by the enteral 
formula as such (20,21). The use of fiber-enriched formulas helps 
to regulate bowel function, reducing the incidence of diarrhea 
(14,22) and constipation (increasing bowel movements, if baseline 
frequency is low, and reducing them, if baseline frequency is high) 
(22). The data from this study concur with these findings in that 
the percentage of patients with diarrhea, despite enteral feeding 
(and concomitant treatments which could cause diarrhea), was 
very low. According to clinical criteria, only four (4.3%) patients 
had diarrhea in the first four weeks, and in the last four weeks 
the incidence fell to 1.1% (n = 1). This incidence of diarrhea in 
patients on EN is lower than the rates of 15-20% reported in other 
studies conducted in Spain (23,24). These reported studies were 
focused on ICU and critical ill patients, in contrast to our study, 
which was targeted to general population receiving EN. This fact 
Figure 1. 
Percentage of patients with abnormal values at each visit and statistical differences between visit 1 and visit 3. GGT: Gamma-glutamyl transferase; V1: Visit 1; V2: Visit 2; V3: 
Visit 3. *Statistically significant difference (p < 0.05). Only patients with available data at V1 and V3, for each biochemical marker, were included in the analysis. 
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could explain the observed discrepancy. In addition, there are 
differences in diarrhea criteria between studies (e.g., three vs five 
liquid bowel movements per day). Other complications of enteral 
feeding include the risk of hyperglycemia and refeeding syndrome 
(25,26). Blood tests were performed at all visits to analyze the risk 
of complications. No significant differences were found for most 
biochemical variables between the three visits, with the exception 
of two parameters, albumin and pre-albumin, which increased. 
Mean albumin levels were below normal values at the beginning 
of the study, and reached normal levels at visit 2 (four weeks), 
while pre-albumin was within normal levels at the three visits. 
Other biochemical parameters, including blood glucose, remained 
stable and within normal ranges. With regard to patients whose 
biochemical parameters were outside normal ranges, a general 
improvement was found over the course of the three visits, being 
statistically significant for those with altered glucose, potassium, 
total protein and albumin levels in blood. Thus, a normalization 
of electrolyte balance and glucose levels was observed. It should 
be noted that biochemical basal values could be affected for all 
different factors related with the patient’s clinical background.
Lastly, the enteral formula was well tolerated and highly accept-
ed. Only one patient (0.9%) had a gastrointestinal complication 
(acute diarrhea), possibly related to the administration of the EN 
formula. Another patient (0.9%) had an adverse event (drug inter-
action with raised GGT), probably related to the administration of 
EN. Only one hyperglycemic event, not related to enteral feeding, 
was recorded, despite 20.6% of the patients being diabetics. No 
cases of refeeding syndrome were reported. 
This study is limited by the fact that there was no control 
group in the study and the intervention group had a wide range 
of diseases. In addition, population was not uniform. Outpatients 
and hospitalized patients were included. Studies performed in 
the future in homogeneous patient groups with specific diseases 
may provide a more precise overview of the benefits and tolera-
bility of the product. Moreover, the lack of available data on bowel 
movements previous to TFF administration limits the interpretation 
of TFF effects on bowel habits. Given that 20% of patients were 
diabetic, another limitation is the lack of exhaustive records about 
glycosylated hemoglobin A1c, type of diabetes and its treatment.
In conclusion, during the course of the study, most patients 
showed a significant increase in weight, BMI, pre-albumin and 
albumin levels, while blood glucose levels and other biochemical 
parameters remained stable. In addition, patients’ stool patterns 
were kept stable within normal limits throughout the study. The 
high-calorie, high-protein enteral formula, enriched with fiber, FOS, 
and monounsaturated fatty acids (Jevity® Plus HP) was found to be 
well tolerated by patients and was beneficial in the management of 
patients who were malnourished or at risk of malnutrition.
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